Skip to main content

Table 4 Cancer-specific and all-cause survival by category of comorbidity among those with Stage I-III disease

From: A retrospective cohort study of patients with stomach and liver cancers: the impact of comorbidity and ethnicity on cancer care and outcomes

  Cancer-specific mortality Hazard Ratios (95% CI)
Impact of comorbidity evaluated at C3 Score of:* Unadjusted Model 11 Model 22
0 1.00 1.00 1.00
1 1.38 (1.11-1.71) 1.33 (1.04-1.71) 1.24 (0.96-1.6)
2 1.68 (1.2-2.36) 1.56 (1.05-2.31) 1.36 (0.91-2.04)
3 1.86 (1.26-2.74) 1.62 (1.03-2.54) 1.34 (0.84-2.13)
6 1.68 (1.08-2.61) 1.15 (0.71-1.87) 0.85 (0.51-1.4)
  All-cause mortality Hazard Ratios (95% CI)
C3 score* Unadjusted Model 11 Model 22
0 1.00 1.00 1.00
1 1.30 (1.06-1.6) 1.25 (0.99-1.58) 1.17 (0.92-1.48)
2 1.57 (1.14-2.17) 1.43 (0.99-2.07) 1.27 (0.87-1.85)
3 1.77 (1.23-2.56) 1.54 (1.01-2.35) 1.28 (0.83-1.99)
6 1.97 (1.33-2.9) 1.44 (0.93-2.23) 1.04 (0.66-1.63)
  1. 1Adjusted for age, sex, site, stage, ethnicity, deprivation and rurality 2 Adjusted for all previous variables plus receipt of treatment. * evaluation of the OR at a score of 1, 2, 3 and 6 (in relation to a score of 0). No results are presented beyond 6 as the 95th percentile of the C3 Index score distribution was 6.74, which means estimates of the OR beyond this point on the scale are of limited utility.